Exero Medical

Company Overview

Snapshot

Founded in September 2018 by Matan BenDavid, Exero Medical operates with 11–50 employees. The company has raised $16.1M across 5 funding rounds from 8 investors. In February 2025, Exero Medical secured funding from lead investors.

Business overview

Exero Medical develops advanced monitoring solutions for the early detection of anastomotic leaks following gastrointestinal surgery. Its core product, the xBar system, is a biodegradable wireless sensor designed to continuously monitor the anastomosis area, providing early warnings of potential leaks to physicians. This technology aims to prevent severe complications and improve patient outcomes in GI surgeries, such as colorectal and bariatric procedures, by enabling timely intervention. The company operates within the Health Tech & Life Sciences sector, specifically focusing on medical devices, digital healthcare, and patient remote monitoring.

Strategic signal

In May 2026, Exero Medical reported positive results from its pivotal study, demonstrating the xBar monitoring system's effectiveness in early detection of colorectal surgery complications. This milestone provides strong clinical validation for their technology, signaling to investors and the medical community the potential for improved patient safety and reduced healthcare costs in post-operative care.

Company Intelligence Q&A

What is Exero Medical's primary focus?

Exero Medical focuses on developing advanced monitoring solutions for the early detection of anastomotic leaks after gastrointestinal surgery, aiming to prevent complications and improve patient outcomes.

When did Exero Medical complete enrollment for its US pivotal study?

Exero Medical completed enrollment of 222 patients for its US pivotal study for early detection of post-operative gastrointestinal surgery complications in September 2025.

Which investors participated in Exero Medical's February 2025 funding round?

In February 2025, Exero Medical received funding from lead investors.

What was a significant regulatory achievement for Exero Medical?

In December 2020, the FDA granted breakthrough device designation for Exero Medical's wireless system, designed for the early detection of potentially lethal anastomotic leaks following gastrointestinal surgery.

What were the results of Exero Medical's pivotal study announced in May 2026?

In May 2026, Exero Medical announced positive results from its pivotal study, demonstrating the xBar monitoring system's ability to detect colorectal surgery complications early.